World Journal of Surgery

, Volume 36, Issue 2, pp 310–317 | Cite as

BRAFV600E Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer

  • Su-jin Kim
  • Kyu Eun Lee
  • Jun Pyo Myong
  • Jeong-hwan Park
  • Yoon Kyung Jeon
  • Hye Sook Min
  • So Yeon Park
  • Kyeong Cheon Jung
  • Do Hoon Koo
  • Yeo-Kyu YounEmail author



The BRAFV600E mutation is the most common genetic alteration found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more frequently in patients with PTC showing aggressive clinicopathologic features. The aim of the present study was to evaluate the prevalence of the BRAFV600E mutation in tumor samples and its association with high-risk clinicopathologic features prospectively.

Patients and methods

From February 2009 to January 2010, 547 PTC patients who underwent surgery in Seoul National University Hospital were enrolled in the study. Polymerase chain reaction was used to amplify exon 15 of the BRAF gene from paraffin-embedded thyroid tumor specimens, followed by direct sequencing to detect the BRAFV600E mutation. Both univariate and multivariate analyses were performed to analyze associations between the BRAFV600E mutation and clinicopathologic features.


The BRAFV600E mutation was found in 381/547 (69.7%) patients with primary PTC. The BRAFV600E mutation was significantly associated with age (≥45 years), tumor size (>1 cm), extrathyroidal extension, and cervical lymph node metastases (P < 0.05). Multiple logistic regression showed that it was significantly associated with gender (OR = 1.834; 95% CI 1.021–3.463), tumor size (OR = 1.972; 95% CI 1.250–3.103), and extra-thyroidal extension (OR = 2.428; 95% CI 1.484–3.992), but not with age, multifocality, lymph node metastases, and advanced disease stage. The proportion of BRAFV600E mutation was significantly associated with the number of high-risk factors of tumor recurrence (P < 0.001).


The BRAFV600E mutation was associated with high-risk clinicopathologic characteristics in patients with PTC. The BRAFV600E mutation may be a potential prognostic factor in PTC patients.


Thyroid Cancer Papillary Thyroid Cancer Differentiate Thyroid Cancer Extrathyroidal Extension BRAFV600E Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRefGoogle Scholar
  2. 2.
    Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319PubMedCrossRefGoogle Scholar
  3. 3.
    Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochem Biophys Acta 1653:25–40PubMedGoogle Scholar
  4. 4.
    Hilger RA, Scheulen ME, Strumberg D (2002) The Ras-Raf-MEKERK pathway in the treatment of cancer. Onkologie 25:511–518PubMedCrossRefGoogle Scholar
  5. 5.
    Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518PubMedCrossRefGoogle Scholar
  6. 6.
    Ries LAG, Melbert D, Krapcho M et al. (2007) SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute., based on November 2006 SEER data submission, posted to the SEER web site
  7. 7.
    Mazzaferri EL (2006) An overview of the management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P (eds) Practical Management of Thyroid Cancer: A Multidisciplinary Approach. Springer-Verlag, London, pp 1–28CrossRefGoogle Scholar
  8. 8.
    DeGroot LJ, Kaplan EL, McCormick M et al (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424PubMedCrossRefGoogle Scholar
  9. 9.
    Tanaka K, Sonoo H, Hirono M et al (2005) Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg Today 35:714–719PubMedCrossRefGoogle Scholar
  10. 10.
    Kim KH, Kang DW, Kim SH et al (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818–821PubMedGoogle Scholar
  11. 11.
    Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRefGoogle Scholar
  12. 12.
    Namba H, Nakashima M, Hayashi T et al (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–4397PubMedCrossRefGoogle Scholar
  13. 13.
    Vasko V, Hu S, Wu G et al (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265–5269PubMedCrossRefGoogle Scholar
  14. 14.
    Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379PubMedCrossRefGoogle Scholar
  15. 15.
    Fugazzola L, Mannavola D, Cirello V et al (2004) BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 61:239–243CrossRefGoogle Scholar
  16. 16.
    Puxeddu E, Moretti S, Elisei R et al (2004) BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414–2420PubMedCrossRefGoogle Scholar
  17. 17.
    Ito Y, Yoshida H, Maruo R et al (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathologic features and disease-free survival of patients. Endocrine J 56:89–97CrossRefGoogle Scholar
  18. 18.
    Nucera C, Goldfarb M, Hodin R et al (2009) Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E). Biochimica et Biophysica Acta 1795(2):152–161PubMedGoogle Scholar
  19. 19.
    Lee JH, Lee ES, Kim YS (2007) Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. Cancer 110:38–46PubMedCrossRefGoogle Scholar
  20. 20.
    Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742–762PubMedCrossRefGoogle Scholar
  21. 21.
    Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364–368CrossRefGoogle Scholar
  22. 22.
    Lee JH, Lee ES, Kim YS et al (2006) BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38:201–204PubMedCrossRefGoogle Scholar
  23. 23.
    Kim KH, Suh KS, Kang DW et al (2005) Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto’s thyroiditis. Pathol Int 55:540–545PubMedCrossRefGoogle Scholar
  24. 24.
    Park SY, Park YJ, Lee YJ et al (2006) Analysis of differential BRAF (V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107:1831–1838PubMedCrossRefGoogle Scholar
  25. 25.
    Lupi C, Giannini R, Ugolini C et al (2007) Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085–4090PubMedCrossRefGoogle Scholar
  26. 26.
    Kebebew E, Weng J, Bauer J et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–471PubMedCrossRefGoogle Scholar
  27. 27.
    Elisei R, Ugolini C, Viola D et al (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Clin Endocrinol Metab 93:3943–3949CrossRefGoogle Scholar
  28. 28.
    Trovisco V, Soares P, Preto A et al (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446:589–595PubMedCrossRefGoogle Scholar
  29. 29.
    Abubaker J, Jehan Z, Bavi P et al (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93:611–618PubMedCrossRefGoogle Scholar
  30. 30.
    Liu RT, Chen YJ, Chou FF et al (2005) No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461–466CrossRefGoogle Scholar
  31. 31.
    Guan H, Ji M, Bao R et al (2009) Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94:1612–1617PubMedCrossRefGoogle Scholar
  32. 32.
    Frasca F, Nucera C, Pellegriti G et al (2008) BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191–205PubMedCrossRefGoogle Scholar
  33. 33.
    Vriens MR, Suh I, Moses W et al (2009) Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 19:1343–1349PubMedCrossRefGoogle Scholar
  34. 34.
    Jo YS, Li S, Song JH et al (2006) Influence of the BRAFV600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667–3670PubMedCrossRefGoogle Scholar
  35. 35.
    Fugazzola L, Puxeddu E, Avenia N et al (2006) Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455–464PubMedCrossRefGoogle Scholar
  36. 36.
    Rodolico V, Cabibi D, Pizzolanti G et al (2007) BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid ≤ 1 cm and their paired lymph node metastases. Cancer 110:1218–1226PubMedCrossRefGoogle Scholar
  37. 37.
    Powell N, Jeremiah S, Morishita M et al (2005) Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205:558–564PubMedCrossRefGoogle Scholar
  38. 38.
    Xu X, Quiros RM, Gattuso P et al (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561–4567PubMedGoogle Scholar
  39. 39.
    Chung KW, Yang SK, Lee GK et al (2006) Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65:660–666CrossRefGoogle Scholar
  40. 40.
    Kim TY, Kim WB, Song JY et al (2005) The BRAF mutation is not associcated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588–593CrossRefGoogle Scholar
  41. 41.
    Renshau AA (2005) Papillary carcinoma of the thyroid ≤ 1.0 cm: rarely incidental or occult anymore. Cancer 105:217–219CrossRefGoogle Scholar
  42. 42.
    Pelizzo MR, Boschin IM, Toniato A et al (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25:547–552PubMedCrossRefGoogle Scholar
  43. 43.
    Park YJ, Kim YA, Lee YJ et al (2010) Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clicnicopathological features, and immunohistochemical findings. Head Neck 32:38–45PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  • Su-jin Kim
    • 1
  • Kyu Eun Lee
    • 2
    • 3
  • Jun Pyo Myong
    • 4
  • Jeong-hwan Park
    • 5
  • Yoon Kyung Jeon
    • 5
  • Hye Sook Min
    • 5
  • So Yeon Park
    • 5
  • Kyeong Cheon Jung
    • 5
  • Do Hoon Koo
    • 6
  • Yeo-Kyu Youn
    • 2
    • 3
    Email author
  1. 1.Department of Surgery, Haeundae Paik HospitalInje University College of MedicineBusanKorea
  2. 2.Department of SurgerySeoul National University College of Medicine and HospitalSeoulKorea
  3. 3.Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  4. 4.Graduate School of MedicineThe Catholic University of KoreaSeoulKorea
  5. 5.Department of PathologySeoul National University College of MedicineSeoulKorea
  6. 6.Department of SurgerySeoul National University Boramae Medical CenterSeoulKorea

Personalised recommendations